Current Edition

children

Racing rival Pfizer, Merck’s Vaxneuvance makes its case for an FDA approval in children

Time is of the essence for Merck as the company races with rival Pfizer to gain an FDA approval for its next-generation pneumococcal vaccine in …

Continue Reading →